CD8A and neoplasm: Further studies are now required to define the tumor antigens targeted by these exhausted CD8+ T cells and subsequently to more precisely analyze their specific molecular profiles in order to optimize checkpoint therapies and other immunotherapeutic approaches like vaccination strategies.